Skip to main content
SpringerLink
Log in

Autoimmune neuroinflammation

A repair pathway lost in multiple sclerosis provides a new drug opportunity

  • News & Views
  • Published:

From Nature Immunology

View current issue Submit your manuscript

A study identifies an increase in the tissue-protective factor HB-EGF during the initial stage of multiple sclerosis (MS), which is actively turned off as the disease worsens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Astrocyte-derived HB-EGF increases in CIS but not in established relapsed remitting MS.

References

  1. Linnerbauer, M. et al. Nat. Immunol. https://doi.org/10.1038/s41590-024-01756-6 (2024).

    Article  PubMed  Google Scholar 

  2. Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A. & Fugger, L. Nat. Rev. Immunol. 22, 734–750 (2022).

    Article  CAS  PubMed  Google Scholar 

  3. Kaufmann, M. et al. Nat. Neurosci. 25, 944–955 (2022).

    Article  CAS  PubMed  Google Scholar 

  4. Escartin, C. et al. Nat. Neurosci. 24, 312–325 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hayakawa, K. et al. Nature 535, 551–555 (2016).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mayo, L. et al. Nat. Med. 20, 1147–1156 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Koretsky, M. J. et al. Brain 146, 4486–4494 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

K.E.A. and L.F. are supported by the Oak Foundation.

Author information

Authors and Affiliations

  1. Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark

    Lise Torp Jensen & Lars Fugger

  2. Oxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK

    Lise Torp Jensen, Kathrine E. Attfield & Lars Fugger

  3. MRC Translational Immune Discovery Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK

    Lars Fugger

Authors
  1. Lise Torp Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathrine E. Attfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lars Fugger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lars Fugger.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jensen, L.T., Attfield, K.E. & Fugger, L. A repair pathway lost in multiple sclerosis provides a new drug opportunity. Nat Immunol 25, 385–386 (2024). https://doi.org/10.1038/s41590-024-01765-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-024-01765-5

  • Springer Nature America, Inc.

Search

Navigation